The International Journal of Cancer has just published the results of an experimental therapy tested on mice. The research, led by the Signaling Lab research group of the UPV/EHU's Faculty of Medicine and Pharmacy and the Department of Pharmacology, Pharmacy and Pharmaceutical Technology of the University of Santiago de Compostela, achieved an 80 percent reduction in liver metastasis brought about by colon cancer.
A key cell process that could cause damage to bile ducts and help explain some liver diseases has been identified by scientists.
Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine gastrointestinal hormone, can significantly and rapidly decrease liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The findings represent an important proof-of-concept for the compound as there are currently no Food and Drug Administration-approved treatments for NAFLD and NASH.
Bacteria found in the small intestines of mice and humans can travel to other organs and trigger an autoimmune response, according to a new Yale study. The researchers also found that the autoimmune reaction can be suppressed with an antibiotic or vaccine designed to target the bacteria, they said.
New research published in The Journal of Physiology indicates that an obese pregnant mother and exposure to a high fat, high sugar diet during pregnancy produces a 'fatty liver' in the fetus, potentially predisposing children to obesity, metabolic and cardiovascular disorders later in life.
Texas A&M University System researchers in collaboration with the Department of Veterans Affairs and Baylor Scott & White Research Institute have completed a study identifying one of the mechanisms leading to the development of non-alcoholic fatty liver disease, or NAFLD, providing new possibilities for prevention and treatment of the disease.
Researchers at the Stanford University School of Medicine have identified elevated tissue iron as a risk factor for life-threatening fungal infections in lung transplant recipients.
Scientists at Imperial College London have become the first in the world to test how pathogens interact with artificial human organs.
A study has revealed that a new scanning technology could almost halve the number of liver biopsies carried out on people with fatty liver disease.
In a new Johns Hopkins study of patient and graft survival trends for pediatric liver transplant recipients between 2002 and 2015, researchers found that outcomes for alternatives to whole liver transplantation (WLT), such as splitting a liver for two recipients or using a part of a liver from a living donor, have improved significantly.